Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects

Core Insights - Corcept Therapeutics Incorporated (NASDAQ:CORT) is recognized as a strong biotech investment by Wall Street analysts, with a Buy rating and a price target of $145 due to its growth potential despite facing commercial challenges [1] Financial Performance - Sales of Corcept's Korlym medication are projected to grow by 19% to 26% year over year, with a 40% increase in volume over the past two quarters, supporting the company's guidance of $800-$850 million [2] Product Pipeline - Corcept is preparing to launch relacorilant for Cushing's syndrome, with anticipated sales reaching $4.3 billion by 2034, indicating a robust product pipeline [3] Market Sentiment - Wolfe Research initiated coverage of Corcept with a Peer Perform rating, expecting the stock to trade between $70 and $75 until legal issues are resolved, while acknowledging the potential of relacorilant [4] Company Overview - Corcept Therapeutics develops drugs that modulate cortisol to treat severe metabolic, oncologic, and neuropsychiatric disorders, with its first approved drug, Korlym, targeting Cushing's Syndrome [5]